Phase 3 Epilepsy Trial, Recruiting NCT05674552 Sponsor: Sohag University Condition: Epilepsy
Back to Epilepsy

Phase 3 Epilepsy Trial, Recruiting

NCT05674552
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have generalised convulsive status epilepticus (a prolonged, severe seizure or repeated seizures without recovery) that has not responded to standard treatments

Who may not be able to join:

  • People for whom informed consent has not been obtained
  • People who have recently consumed ketone supplements, followed a ketogenic (very high-fat, low-carbohydrate) diet, or made other specific dietary changes
  • People with unstable blood pressure, heart function, or breathing
  • People who have had a traumatic brain injury
  • People with blood sugar levels that are too low or too high
  • People with a condition where the blood is too acidic (metabolic acidosis)
  • People who already have elevated ketone levels in the body (a blood ketone level above 2 mmol/L)
  • People with serious conditions affecting the liver, kidneys, lungs, heart, digestive system, hormonal system, or immune system
  • People who are malnourished or classified as obese
  • People for whom a feeding tube through the nose and into the stomach cannot be used
  • People with inherited conditions that affect how the body processes nutrients (inborn errors of metabolism)
  • People with allergies or other medical reasons that would prevent the use of ketone ester supplements
  • People who are currently receiving, or have received within the last 24 hours, a medication called propofol
  • People who are taking medications known as carbonic anhydrase inhibitors (confirm with trial site for specific examples)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Abdelrahim A Sadek, MD, PhD, Sohag University

Phone: 01114232126

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
10 January 2023
Est. completion
30 June 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Proportion of patients achieving electroclinical cessation of seizures

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov